InVitria, a division of Ventria Bioscience, was created to provide the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria accomplishes this by allowing customers to eliminate animal components from cell-based processes. Removing these components helps to improve consistency, safety and efficiency.
InVitria’s products are recombinant proteins that are manufactured at its manufacturing facility in Junction City, Kansas. These products have many uses across the life science industry, including applications related to regenerative medicine, cellular therapy, biomanufacturing, vaccines, diagnostics and medical devices.
Dr. Randall Alfano joined InVitria in 2012 and now leads the product development team, where he utilizes his expertise in media design and optimization for biomanufacturing and stem/primary cells. Prior to joining the company, Dr. Alfano was the Process Development Manager for XBiotech in Austin, TX where he specialized in the development and optimization of the company’s cell culture processes in mammalian cells for cancer biologics.
I am honored to release this interview with Dr. Alfano, in which we explore the formation of InVitria, as well as its innovative product portfolio, mission, and future goals. We also explore trends occurring within the broader cell therapy industry. Enjoy learning about InVitria’s role in accelerating life changing medicines through its unique portfolio of blood-free components, supplements, and media.